BioLineRx Ltd. (BLRX) stock
BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 3/30
$1.15+0.03 (+2.68%)
Close on Nov 18, 2026Market cap $5.00MP/E –Yield –
BioLineRx revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
For fiscal 2025 it was $1.18M, down 95.9% from the year before. The highest annual figure on record is $28.94M in fiscal 2024.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.18M | -95.9% |
| FY2024 | Dec 31, 2024 | $28.94M | +502.9% |
| FY2023 | Dec 31, 2023 | $4.80M | – |
| FY2022 | Dec 31, 2022 | $0 | – |
| FY2021 | Dec 31, 2021 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $294.00K | – |
| Q2 FY2025 | Jun 30, 2025 | $304.00K | – |
| Q2 FY2024 | Jun 30, 2024 | $5.39M | – |
| Q2 FY2023 | Jun 30, 2023 | $0 | – |
See a number that looks wrong?